Management of Mixed Dyslipidemia with Fenofibrate and Statins

Initial Approach: Statin Monotherapy

The European Society of Cardiology recommends statins as the first-line therapy for mixed dyslipidemia, with the goal of achieving LDL-C targets, and then adding fenofibrate if triglycerides remain elevated or HDL-C remains low despite maximally tolerated statin therapy 1, 2
For very high-risk patients, the American College of Cardiology recommends targeting LDL-C <70 mg/dL with high-intensity statin therapy, such as atorvastatin 40-80 mg or rosuvastatin 20-40 mg 1, 2, 3
For high-risk patients, the American College of Cardiology recommends targeting LDL-C <100 mg/dL with moderate- to high-intensity statin therapy 1, 2, 3
Higher-dose statins, such as atorvastatin 40-80 mg, provide moderate triglyceride reduction and may obviate the need for combination therapy in some patients 4

The American Diabetes Association recommends adding fenofibrate to statin therapy in patients with type 2 diabetes and mixed dyslipidemia if triglycerides remain elevated after achieving LDL-C target with statin 1, 4
The American College of Cardiology recommends adding fenofibrate to statin therapy in patients with severe hypertriglyceridemia (triglycerides >400 mg/dL) to reduce pancreatitis risk, even if LDL-C is at goal 4
The American College of Cardiology recommends considering combination therapy in patients with persistent mixed dyslipidemia, defined as triglycerides 200-400 mg/dL with low HDL-C despite maximally tolerated statin therapy 4

The American College of Cardiology recommends starting with low-dose combination therapy to minimize myopathy risk, such as fenofibrate 160 mg daily plus atorvastatin 5-20 mg daily, or fenofibrate 160 mg daily plus rosuvastatin 10-20 mg daily 2

The National Kidney Foundation recommends assessing lipid response at 4-8 weeks after initiating combination therapy, including measuring total cholesterol, LDL-C, HDL-C, triglycerides, and checking liver enzymes and creatine kinase for safety monitoring 5
The National Kidney Foundation recommends monitoring renal function, especially in patients with chronic kidney disease, and adjusting the dose of fenofibrate accordingly 5

The American College of Cardiology recommends avoiding fenofibrate in patients with severe renal impairment, active liver disease, preexisting gallbladder disease, or known hypersensitivity to fenofibrate or fenofibric acid 4

The American College of Cardiology recommends avoiding gemfibrozil-statin combinations due to significantly higher myopathy risk compared to fenofibrate-statin combinations 4